Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q3 2024 (← Previous) (Next →)

Filing Date: Nov 8, 2024

Total Value ($000): $63,574 (100.0% shares, 0.0% debt)

Holdings (6)

CRSP CRISPR Therapeutics AG 36.8%

Value ($000) $23,422 Shares 498,558 Est. Cost $40.26 Unrealized +26.0%

CTNM Contineum Therapeutics, Inc. 27.6%

Value ($000) $17,574 Shares 918,163 Est. Cost $16.10 Unrealized +19.1%

— Repare Therapeutics, Inc. 14.3%

Value ($000) $9,105 Shares 2,646,657 Est. Cost $10.58 Unrealized —

SKYE Skye Bioscience, Inc. 12.3%

Value ($000) $7,850 Shares 2,007,704 Est. Cost $7.75 Unrealized -27.6%

— Adverum Biotechnologies, Inc. 5.6%

Value ($000) $3,558 Shares 506,821 Est. Cost $9646.10 Unrealized —

— Gritstone Oncology, Inc. 3.2%

Value ($000) $2,065 Shares 3,561,150 Est. Cost $7767.86 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	498,558	$23,422	36.8%	$40.26	+26.0%	Common Shares	H17182108
CTNM	Contineum Therapeutics, Inc.	918,163	$17,574	27.6%	$16.10	+19.1%	Common Stock	21217B100
—	Repare Therapeutics, Inc.	2,646,657	$9,105	14.3%	$10.58	—	Common Stock	760273102
SKYE	Skye Bioscience, Inc.	2,007,704	$7,850	12.3%	$7.75	-27.6%	Common Stock	83086J200
—	Adverum Biotechnologies, Inc.	506,821	$3,558	5.6%	$9646.10	—	Common Stock	00773U108
—	Gritstone Oncology, Inc.	3,561,150	$2,065	3.2%	$7767.86	—	Common Stock	39868T105